SCHEMBL6489046

SCHEMBL6489046

CCCSc1cccc(C(=O)O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 1/20 0.65
HSD17B10 Q99714 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
HPGD P15428 1/20 0.59
KMT2A Q03164 2/20 0.53
MAP1LC3B Q9GZQ8 1/20 0.46
MAP1LC3A Q9H492 1/20 0.46
PTPN11 Q06124 1/20 0.45
LTB4R Q15722 1/20 0.45
FOLH1 Q04609 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA6 P23280 1/20 0.44
CA9 Q16790 1/20 0.44
RECQL P46063 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5315791 0.90 APEX1 (0.61) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL6489146 0.87 APEX1 (0.58) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL7814196 0.87 APEX1 (0.58) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL15199295 0.87 APEX1 (0.58) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL1991282 0.86 APEX1 (0.69) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL16344775 0.84 APEX1 (0.67) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL11941049 0.82 PLA2G2A (0.43) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL6477192 0.81 APEX1 (0.63) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL1244912 0.81 APEX1 (0.54) APEX1HSD17B10CYP1A2CYP2C9HPGD
SCHEMBL6477946 0.80 APEX1 (0.56) APEX1HSD17B10CYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP APEX1 1768/4885HSD17B10 1675/4885CYP1A2 1673/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP APEX1 1768/4885HSD17B10 1675/4885CYP1A2 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.